TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01702974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)
Description: Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
Study: NCT03867214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: 1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 100 mL of normal saline intravenously approximately 15 minutes before incision
Study: NCT02228707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: Participants receive BIIB061

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT00778934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intimate Health Gel
Description: Intimate Health Gel
Study: NCT00555958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active, implantable, intra-abdominal vagal blocking medical device
Description: Intermittent, programmable, intra-abdominal vagal blocking
Study: NCT02231112

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole breast RT on prone position
Study: NCT01672385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring plus self-management support
Description: Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
Study: NCT00382668

Intervention type: DRUG
Intervention: Dasatinib
Description: Tablets, Oral, 50 mg, once daily, for one day

Intervention type: DRUG
Intervention: Dasatinib
Description: Tablets, Oral, 20 mg, once daily for one day

Intervention type: DRUG
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg, once daily for one day
Study: NCT01608711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-1C4D4
Description: Intravenous Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Intravenous Infusion
Study: NCT01731912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo standard EBRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02446977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B2 Streuli®
Description: 4ml IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Solution for injection
Description: 4ml IV
Study: NCT00875186

Intervention type: OTHER
Intervention: aerobic endurance training
Description: participants exercises 2 times weekly for 1 hour (aerobic endurance training)

Intervention type: OTHER
Intervention: aerobic endurance training
Description: participants exercised 1 time weekly for 1 hour (aerobic endurance training)
Study: NCT03777358

Intervention type: DEVICE
Intervention: 3D-TVS
Description: The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then hysteroscopy will be performed
Study: NCT00935181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: respiratory muscle stretching
Description: stretching exercises for respiratory muscles like diaphragm, pectoral, dorsalis etc
Study: NCT03010696

Intervention type: OTHER
Intervention: No interventions, questionnaire, collect specimen

Intervention type: OTHER
Intervention: No interventions, questionnaire, collect specimen
Study: NCT03972059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training - Phase 1
Description: Phase 1 is the first 4 weeks of the 12-week training program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training - Phase 2
Description: Phase 2 is the next 4 weeks following phase 1 of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in phase 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training - Phase 3
Description: Phase 3 is the last 4 weeks of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in the previous phases.
Study: NCT03816033

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Catheter ablation treatment for the treatment of the studied arrhythmias

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency catheter ablation
Description: Catheter ablation treatment for the treatment of the studied arrhythmias
Study: NCT00346216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 100 to 200 mg twice daily, taken by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: ibuprofen 600 mg to 800 mg three times daily, taken by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: naproxen 375mg to 500 mg twice daily, taken by mouth
Study: NCT02324946

Intervention type: OTHER
Intervention: Mass Screening
Description: Preoperative screening with STOP-BANG and DES-OSA scores and postoperative comparison with difficult intubation / ventilation scores.
Study: NCT03115359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Therapy
Description: The Mindfulness Based Therapy intervention will teach participants the mindfulness meditation-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: The Cognitive Behavioral Therapy (CBT) intervention will teach participants the CBT-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
Study: NCT03856060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT04279132

Intervention type: BEHAVIORAL
Intervention: POSTOPERATIVE COGNITIVE DYSFUNCTION
Description: NEURON SPECIFIC ENOLASE LEVELS IN LUMBAR DISC HERNIECTOMY WITH GENERAL ANESTHESIA MODALITIES

Intervention type: BEHAVIORAL
Intervention: POSTOPERATIVE COGNITIVE DYSFUNCTION
Description: NEURON SPECIFIC ENOLASE LEVELS IN LUMBAR DISC HERNIECTOMY WITH GENERAL ANESTHESIA MODALITIES
Study: NCT03856060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Watch videos of doctor and patient interaction in different settings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Watch videos of doctor and patient interaction in different settings
Study: NCT02792673

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryos will be transferred using a medium of 0.5 mg/mL of Hyaluronan-enriched medium (EmbryoGlue®, Vitrolife, Sweden)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryos will be transferred using a medium of 30% Protein-supplemented Culture Medium (Global total®, Life Global group, Canada)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a novel technique in which embryos will be transferred using a medium of autologous Follicular Fluid
Study: NCT03760029

Intervention type: OTHER
Group type: OTHER
Intervention: Visit frequency
Description: All subjects need to visit sites more frequently than in routine clinical practice.
Study: NCT03392896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PHXC
Description: DCR-PHXC is a novel, potent, and long-acting small interference ribonucleic acid (siRNA) molecule conjugated to N-acteylgalactosamine (GalNAc) that is designed to decrease liver oxalate production. DCR-PHXC is delivered via subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PHXC
Description: DCR-PHXC is a novel, potent, and long-acting small interference ribonucleic acid (siRNA) molecule conjugated to N-acteylgalactosamine (GalNAc) that is designed to decrease liver oxalate production. DCR-PHXC is delivered via subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single SC administration of placebo, which will be a sterile, preservative-free normal saline 0.9% solution for SC injection, which is of similar osmolality to the DCR-PHXC formulation.
Study: NCT00473434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: 3mg or 6mg or 9mg or 12mg once daily for 52 weeks
Study: NCT02792673

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Labotect embryo transfer catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Labotect embryo transfer catheter
Study: NCT02792673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labotect embryo transfer catheter
Study: NCT04025346

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsimax
Description: 1 capsule to be taken before breakfast.
Study: NCT03900832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gardner walking protocol
Description: The Gardner protocol begins at 2 mph and 0% grade for 2 minutes. The grade increases by 2% every 2 minutes (the speed remains 2 mph) until the subject says they want to stop or 22 minutes maximum. BP and HR will also be measured throughout the protocol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gardner walking protocol
Description: The Gardner protocol begins at 2 mph and 0% grade for 2 minutes. The grade increases by 2% every 2 minutes (the speed remains 2 mph) until the subject says they want to stop or 22 minutes maximum. BP and HR will also be measured throughout the protocol.
Study: NCT01285401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VigantOL oil plus interferon beta-1a (Rebif)
Description: VigantOL oil 6,670 International Units per day (IU/d) (167 microgram per day \[mcg/day\]), was administered orally for 4 weeks followed by 14,007 IU/d (350 mcg/d) administered orally for 44 weeks on top of Rebif 44mcg three times per week (tiw) administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus interferon beta-1a (Rebif)
Description: Matching placebo daily, orally administered matched placebo for 48 weeks on top of Rebif 44 mcg tiw.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Rebif®) alone
Description: Rebif® 44 mcg tiw, sub-cutaneously alone.
Study: NCT03581942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: (MTD) Dose Escalation level 2: Ibrutinib 840 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: (MTD) Copanlisib 60 mg weekly (3w on/1w off)
Study: NCT02384551

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Carbohydrate
Description: 9 week menu of dietary carbohydrate modification

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Carbohydrate
Description: 9 week menu of dietary carbohydrate modification

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Carbohydrate
Description: 9 week menu of dietary carbohydrate modification

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Carbohydrate
Description: 9 week menu of dietary carbohydrate modification
Study: NCT04218968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and carvedilol titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the adrenergic blocker carvedilol, resulting in a decreased clinical phenoconversion rate to parkinsonism.
Study: NCT02370329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ropeginterferon Alfa-2B
Description: Given SC
Study: NCT04025346

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsimax
Description: 1 capsule to be taken before breakfast.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micro Crystalline Cellulose
Description: 1 capsule to be taken before breakfast.
Study: NCT01874197

Intervention type: DEVICE
Group type: OTHER
Intervention: B-TEVAR device
Description: Implantation of the Branched Thorcoabdominal aortic anerysm device
Study: NCT02529852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I Starting Dose Level: 15 mg by mouth on Days 1 - 14 of each 21 day cycle.~Phase II Starting Dose Level: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Phase I and II: 1000 mg by vein on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Phase I and II: 750 mg/m2 vein over about 1 hour on Day 1 of all cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Phase I and II: 50 mg/m2 by vein over about 15 minutes each on Day 1 of all cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Phase I and II: 1.4 mg/m2 by vein on Day 1 of all cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Phase I and II: 100 mg by mouth daily on Days 1 - 5 of each 21 day cycle.
Study: NCT03532542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casimersen
Description: Casimersen solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golodirsen
Description: Golodirsen solution for IV infusion
Study: NCT03354013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AOA
Description: 100% ICSI-AOA will be performed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genetic screening
Description: Patients will donate a saliva sample. Genetic screening will take place for PLCzeta (male) and Dux4 (male and female). Also other possible genes involved in embryo development could be tested.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Calcium pattern analysis
Description: Male patients will donate a sperm sample. Calcium pattern analysis will take place by injecting the patients' sperm into mouse and/or human (in vitro matured) oocytes (research-donated control oocytes). This will estimate the sperm capability to induce calcium oscillations in the oocyte.
Study: NCT01904188

Intervention type: DEVICE
Intervention: Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z regularly)
Description: The Gene Z device or other rapid diagnostic techniques that we have developed in our lab will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device or other rapid diagnostic techniques developed in our lab will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results
Study: NCT03802578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAND EXERCISE
Study: NCT00938158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: single dose of subcutaneously injected albiglutide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: single dose of subcutaneously injected albiglutide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: single dose of subcutaneously injected albiglutide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: single dose of subcutaneously injected albiglutide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: single dose of subcutaneously injected albiglutide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: single dose of subcutaneously injected albiglutide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: single dose of subcutaneously injected albiglutide
Study: NCT05043363

Intervention type: DEVICE
Intervention: LumenEye X1 digital rectoscope
Description: The LumenEye X1 is a novel digital rectoscope that introduces digital HD imaging and improved ergonomics to conventional rigid sigmoidoscopy.
Study: NCT01968486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDT standard fluence, ranibizumab
Description: In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT standard fluence (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 mW/cm2 for 83 s). Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDT reduced fluence, ranibizumab
Description: In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT reduced fluence ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s).Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: In the ranibizumab monotherapy arm patients were treated with a loading phase of three consecutive 0.5 mg (10 mg/ml) IVR injections every six weeks. Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
Study: NCT04401735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotides
Description: PDRN injection to epidural space

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotides
Description: PDRN injection to epidural space

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline
Study: NCT01493323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of personality traits
Description: suicide behaviour , psychic pain, social exclusion, decision making...

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of personality traits
Description: suicide behaviour , psychic pain, social exclusion, decision making...

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of suicidal act
Description: suicide behaviour , psychic pain, social exclusion, decision making...

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of suicidal act
Description: suicide behaviour , psychic pain, social exclusion, decision making...

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of depression
Description: suicide behaviour , psychic pain, social exclusion, decision making...

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of depression
Description: suicide behaviour , psychic pain, social exclusion, decision making...

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyber ball game
Description: functional neuroimaging
Study: NCT04025346

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Micro Crystalline Cellulose
Description: 1 capsule to be taken before breakfast.
Study: NCT01493323

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyber ball game
Description: functional neuroimaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task
Description: functional neuroimaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task
Description: functional neuroimaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcomputer
Description: functional neuroimaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcomputer
Description: functional neuroimaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample
Study: NCT01207700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW based intervention post ACS
Description: CHW is trained and supervised to provide interventions that could improved adherence to post ACS care
Study: NCT03701776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Standard of care